The Triglyceride-Glucose Index is a calculated marker, ln(triglycerides × fasting glucose / 2), that serves as a surrogate for insulin resistance when direct insulin testing isn't available.
TyG is one of the most practical insulin resistance markers from a standard lipid + glucose panel. It tracks well with HOMA-IR in population studies and flags metabolic dysfunction early, before fasting glucose or HbA1c move.
Optimal Triglyceride-Glucose Index: 0-4.4 Index.
Typically re-tested every 12 weeks.
It is a derived number, calculated from two fasting blood results, that estimates how well insulin is doing its job without measuring insulin itself.
Nothing new is drawn for it. The index takes the fasting triglyceride value and the fasting glucose value from a routine panel, multiplies them, and applies a logarithm to compress the result onto a readable scale. Because labs use different units and different logarithmic conventions, the same biology can print as a number near 4 on one report and near 9 on another. That is why the value only means something when read against the reference range printed on the same report, never against a number you saw elsewhere.
The logic behind it is straightforward physiology. When cells respond less readily to insulin, two things tend to drift in the same direction. Muscle and fat tissue take up less glucose and the liver releases more of it, so fasting glucose creeps upward. At the same time, insulin loses some of its normal braking effect on fat release from adipose tissue, the liver receives more free fatty acids, and it packages them into triglyceride-rich particles that it exports into the blood. Fasting triglycerides rise. Multiplying the two captures a drift that either one alone might miss, which is the whole point of combining them.
The reference method for insulin sensitivity is the hyperinsulinaemic euglycaemic clamp, a research procedure involving hours of controlled infusions 10. It is not something anyone orders for a check-up. Surrogate indices exist because clinicians and researchers needed something that could be calculated from blood already on file, and this one has the practical advantage of needing no insulin assay at all.
It matters because it tracks a metabolic process that tends to move quietly for years before standard screening flags anything, and because a large body of observational research links higher values to hard outcomes 1.
A systematic review and meta-analysis in general-population cohorts reported that higher values of the index were associated with an increased risk of cardiovascular disease and of mortality 1. That association has been examined separately across several organ systems, which is part of why the marker has attracted so much interest.
For the coronary arteries, a systematic review and meta-analysis found the index was associated not only with the risk of coronary artery disease but also with its severity and with prognosis after it is identified 2. Research in cerebrovascular disease points the same way, with a meta-analysis reporting an association between higher values and ischaemic stroke 3. A further meta-analysis described an association with heart failure 4.
The kidneys show up too. A cohort study combined with a meta-analysis reported an association between higher values and chronic kidney disease 5, and a separate general-population study found the index was associated with future decline in renal function 6. Among people with hypertension who do not have diabetes, research has examined the index against several different cardiovascular endpoints 7.
Two points of caution belong here. First, these are associations drawn from observational data, which means they describe patterns across populations rather than predicting what will happen to any one person. Second, the index is a surrogate. It infers insulin resistance from downstream consequences rather than measuring the hormone, so it can be nudged by anything that moves triglycerides or glucose for unrelated reasons. Used sensibly, it is an early, inexpensive pointer toward a conversation, not a verdict.
A result inside the standard reference range on your own report is considered unremarkable by the laboratory, while an optimal target sits slightly tighter than the standard range.
| Marker | Standard lab reference range | FitScript optimal range |
|---|---|---|
| Triglyceride-Glucose Index | 0 to 4.5 Index | 0 to 4.4 Index |
Reference ranges are typical lab reference ranges and they vary by laboratory, by age and by sex, as well as by the formula and units a given lab uses to calculate the index. FitScript's optimal range is an optimisation target, not a diagnostic cut-off, and a value outside it does not define a condition. No sex-specific or age-specific targets are published for this marker here, so treating one number as a universal threshold would be a mistake.
The more useful habit is to watch direction rather than a single reading. Research using repeated measurements has looked at longitudinal trajectories of the index rather than one-off values, examining how the pattern over time relates to cardiovascular disease 8. Two people can sit at the same number with one drifting up and one drifting down, and those are different situations.
A result above the standard range suggests that fasting triglycerides, fasting glucose, or both were elevated when the blood was drawn, a pattern commonly interpreted as reduced insulin sensitivity.
Related: Is Fasting Glucose the Same as Fasting Insulin?
What people notice. Insulin resistance is often silent, which is the main reason it goes unnoticed. When people do report something, it tends to be non-specific and easy to attribute to a busy life, including energy dips after carbohydrate-heavy meals, increased hunger between meals, difficulty shifting weight carried around the middle, afternoon fatigue, or skin changes such as darkened, velvety patches in skin folds. None of these confirm anything on their own, and plenty of people with an elevated index notice nothing at all.
Common contributors. Excess visceral fat is among the most consistently studied, and research has looked at the index alongside both classical and newer obesity measures 8. Other recognised contributors include low physical activity, diets high in refined carbohydrate and alcohol, short or fragmented sleep, chronic stress, certain medications, thyroid underactivity, fatty liver, polycystic ovary syndrome, and inherited patterns of high triglycerides. A non-fasting sample is a frequent and entirely technical cause of an inflated number.
What it may mean over time. In population research, higher values are associated with coronary artery disease and its prognosis 2, with ischaemic stroke 3, with heart failure 4 and with declining kidney function 6. In acutely unwell hospitalised populations the marker has also been studied, with one retrospective cohort examining trajectories of the index and all-cause mortality among critically ill patients with atrial fibrillation 9. Critically ill hospital patients are a very different group from someone with a routine outpatient result.
The next step. A single suboptimal value is worth repeating under proper fasting conditions and reading next to the underlying triglyceride and glucose numbers, insulin, and A1C. Bring the result to a clinician rather than acting on it alone, and if it is markedly outside the range or paired with symptoms, it is worth discussing promptly. Never ignore a result that falls outside the standard range.
A low result usually means both fasting triglycerides and fasting glucose were at the lower end of their ranges, which in most people is an unremarkable and generally favourable finding.
What people notice. Typically nothing. A low index is not a symptom-producing state in itself. Where symptoms do accompany a very low value, they usually belong to whatever is driving the underlying numbers rather than to the index, which might include shakiness, light-headedness or sweating between meals in people with low fasting glucose, or unintentional weight loss and fatigue in people with very low triglycerides.
Common contributors. Good insulin sensitivity is the most ordinary explanation, often seen in lean, physically active people and in those eating a diet low in refined carbohydrate and alcohol. Lower values can also reflect a prolonged fast before the draw. Less commonly, unusually low triglycerides may accompany an overactive thyroid, malabsorption, undernutrition, chronic illness or certain inherited lipid conditions, and some medications lower triglycerides substantially. A low fasting glucose has its own set of explanations that a clinician considers in context.
What it may mean over time. For most people, a low value sits with the more favourable end of the risk associations described above. It does not confer protection on its own, and it does not rule out cardiovascular disease, since the index says nothing about blood pressure, LDL particle burden, lipoprotein(a), smoking or family history.
The next step. A low value with no symptoms generally needs no action beyond ordinary follow-up. A low value alongside weight loss, persistent fatigue or symptoms between meals is worth raising with a clinician, who will look at the component results rather than the index.
Quite a lot, which is why one reading rarely settles a question.
Testing conditions matter more than most people expect. Triglycerides are strongly influenced by recent eating, so a short or broken fast can lift the index substantially. Alcohol in the day or two before a draw is a well-recognised cause of higher triglycerides. Acute illness, infection, recent surgery, poor sleep the night before, and the physiological stress that comes with any of those can raise fasting glucose. A very hard training session shortly before testing can move both inputs. Comparing results collected under different conditions, or calculated by different laboratories using different formulas, produces differences that reflect the process rather than your physiology.
Habits linked to the inputs. Reducing visceral fat, increasing regular physical activity including resistance work, improving sleep duration and consistency, reducing alcohol, and shifting away from refined carbohydrate and added sugar are each associated with lower fasting triglycerides or improved glucose handling. These are associations rather than promises, and individual responses differ widely.
Medications and conditions. Several commonly prescribed medicines are associated with changes in one or both inputs. Pregnancy, thyroid disorders, kidney disease and liver disease all influence the components too. A licensed provider evaluates whether any prescription option is appropriate, and no one should start, stop or change a medication on the strength of a calculated index.
The index is not drawn separately. It is calculated from fasting triglycerides and fasting glucose, both of which sit on standard lipid and metabolic panels, so it comes along with routine bloodwork collected after an appropriate fast.
FitScript is built around repeat testing rather than a single snapshot, with 150+ biomarkers tested per year, which is what makes trajectory visible. Because the research on this marker increasingly looks at how values move over time rather than where they sit once 8, a series of results collected under consistent fasting conditions is far more informative than one reading.
Atlas, the AI health advisor, reads the index in context with the rest of the panel, including insulin, A1C, liver markers and the full lipid picture, and writes that interpretation into your FitScript. Interpretation is not diagnosis. Where a result suggests something that warrants clinical attention, or where a prescription option comes into the conversation, a licensed provider reviews the member and decides whether it is appropriate. This page is educational and is not medical advice, and your results and any treatment should be discussed with a clinician or licensed provider.
On its own the index is a summary. Its value comes from reading it with the markers that explain it.
Start with the two inputs, since a raised index is always driven by one or both. Triglycerides tells you how much of the signal comes from lipid handling, and Fasting Glucose tells you how much comes from glucose control. From there, Fasting Insulin measures the hormone the index only infers, and HOMA-IR is a second surrogate calculated from insulin and glucose that often moves in parallel and can corroborate or complicate the picture. Hemoglobin A1C adds a longer time horizon, reflecting average glucose exposure over months rather than the morning of the draw, and Uric Acid is frequently elevated alongside insulin resistance and metabolic syndrome patterns. Because so much of the research on this index concerns the heart and the vessels 1, a broader Heart Health panel covering the wider lipid and inflammatory picture gives the context a single calculated number cannot.
Kidney function markers are also worth reviewing given the associations reported with chronic kidney disease 5, and blood pressure belongs in the same conversation, since the index has been studied specifically among people with hypertension who do not have diabetes 7.
The triglyceride-glucose index is a cheap, repeatable estimate of insulin sensitivity built from two numbers you almost certainly already have. Higher values are associated with cardiovascular and kidney outcomes, lower values usually reflect good metabolic handling, and both are best read as part of a trend rather than a single verdict. Check your fasting conditions, read the number against the range on your own report, look at the component markers, and take anything outside the standard range to a clinician.
Yes. Both inputs are fasting measurements, and triglycerides in particular rise after eating. A short or interrupted fast can inflate the calculated value and make a normal result look suboptimal. Follow the fasting instructions your lab gives, and if you did not fast properly, say so, because the result should be interpreted differently or repeated.
Neither is definitively better. Both are surrogates for insulin resistance rather than direct measurements. The triglyceride-glucose index has the practical advantage of needing no insulin assay, so it can be calculated from panels that are already common and inexpensive. HOMA-IR uses fasting insulin and glucose, which measures the hormone directly. Many clinicians find it useful to look at both alongside A1C.
Because laboratories calculate the index using different units and different logarithmic conventions, the same underlying biology can print on different scales. A value near 4 and a value near 9 can describe the same person. Always read your number against the reference range printed on your own report, and avoid comparing it with a figure from a different source.
No. A calculated index does not identify a condition, and no single blood value does. A suboptimal result suggests that fasting triglycerides, fasting glucose or both were elevated at the time of the draw, which is a prompt to look at the component markers, repeat under proper fasting conditions, and discuss the pattern with a clinician who can consider your full picture.
The inputs can move on different timescales. Fasting triglycerides respond within days to weeks to changes in alcohol, refined carbohydrate and activity, while fasting glucose tends to shift more gradually. Because testing conditions also move the number, meaningful change is best judged over repeat tests collected the same way rather than between two readings taken weeks apart under different circumstances.
Usually not. In most people a low value simply reflects low fasting triglycerides and low fasting glucose, a generally favourable pattern. It is worth raising with a clinician if it comes with unintentional weight loss, persistent fatigue, or symptoms such as shakiness and light-headedness between meals, since those point to the component results rather than the index itself.
Yes. Anything that lowers triglycerides or fasting glucose will pull the index down, and some medicines raise one or both. That means the number can move for pharmacological reasons rather than because the underlying metabolic picture shifted. Tell whoever interprets your panel what you are taking, and never adjust a medication based on a calculated index. A licensed provider evaluates what is appropriate.
Start with the two inputs, fasting triglycerides and fasting glucose, then add fasting insulin, HOMA-IR and hemoglobin A1C for a fuller view of glucose and insulin handling. Uric acid often tracks alongside insulin resistance, and a broader heart health panel adds the lipid and inflammatory context that one calculated number cannot provide on its own.